Related Experiment Video

Updated: Nov 18, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K

Wnt5a: A promising therapeutic target in ovarian cancer

Weijian Zhou1, Jie Mei1, Dingyi Gu1

  • 1Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.

Pathology, Research and Practice
|February 4, 2021
PubMed

Insights

Downregulating Wnt5a, a protein linked to poor prognosis in ovarian cancer, can suppress cancer cell migration and invasion. This suggests Wnt5a is a promising therapeutic target for advanced ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Advanced ovarian cancer lacks effective treatments, remaining a leading cause of cancer death in women.
  • Wnt5a, a member of the noncanonical Wnt pathway, exhibits context-dependent roles in cancer, acting as either a tumor suppressor or oncogene.
  • Elevated Wnt5a expression in ovarian cancer correlates with poor patient prognosis and increased tumor aggressiveness.

Purpose of the Study:

  • To review the mechanisms underlying Wnt5a's role in ovarian cancer.
  • To evaluate the therapeutic potential of targeting Wnt5a in advanced ovarian cancer.

Main Methods:

  • Literature review focusing on Wnt5a signaling in ovarian cancer.
  • Analysis of studies investigating the effects of Wnt5a modulation on ovarian cancer cell behavior.
  • Examination of Wnt5a's association with clinical outcomes in ovarian cancer patients.

Main Results:

  • Wnt5a protein is significantly upregulated in ovarian cancer tissues.
  • Downregulation of Wnt5a expression inhibits ovarian cancer cell migration and invasion.
  • Wnt5a's role in ovarian cancer appears to be oncogenic, promoting metastasis.

Conclusions:

  • Wnt5a is a promising therapeutic target for managing advanced ovarian cancer metastasis.
  • Targeting Wnt5a offers a potential antimetastatic strategy for ovarian cancer patients.
Keywords:
BiomarkerFgrOvarian cancerROR2Wnt5a

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.8K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.0K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K